137 related articles for article (PubMed ID: 19118524)
41. Variation of the gene encoding the nuclear bile salt receptor FXR and gallstone susceptibility in mice and humans.
Kovacs P; Kress R; Rocha J; Kurtz U; Miquel JF; Nervi F; Méndez-Sánchez N; Uribe M; Bock HH; Schirin-Sokhan R; Stumvoll M; Mössner J; Lammert F; Wittenburg H
J Hepatol; 2008 Jan; 48(1):116-24. PubMed ID: 17931734
[TBL] [Abstract][Full Text] [Related]
42. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
Kainuma M; Makishima M; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2007 Apr; 15(7):2587-600. PubMed ID: 17292610
[TBL] [Abstract][Full Text] [Related]
43. Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands.
Kainuma M; Kasuga J; Hosoda S; Wakabayashi K; Tanatani A; Nagasawa K; Miyachi H; Makishima M; Hashimoto Y
Bioorg Med Chem Lett; 2006 Jun; 16(12):3213-8. PubMed ID: 16617018
[TBL] [Abstract][Full Text] [Related]
44. 3D-QSAR studies with the aid of molecular docking for a series of non-steroidal FXR agonists.
Zhang T; Zhou JH; Shi LW; Zhu RX; Chen MB
Bioorg Med Chem Lett; 2007 Apr; 17(8):2156-60. PubMed ID: 17307356
[TBL] [Abstract][Full Text] [Related]
45. Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
Pellicciari R; Gioiello A; Costantino G; Sadeghpour BM; Rizzo G; Meyer U; Parks DJ; Entrena-Guadix A; Fiorucci S
J Med Chem; 2006 Jul; 49(14):4208-15. PubMed ID: 16821780
[TBL] [Abstract][Full Text] [Related]
46. Cytosol-nucleus traffic and colocalization with FXR of conjugated bile acids in rat hepatocytes.
Monte MJ; Rosales R; Macias RI; Iannota V; Martinez-Fernandez A; Romero MR; Hofmann AF; Marin JJ
Am J Physiol Gastrointest Liver Physiol; 2008 Jul; 295(1):G54-G62. PubMed ID: 18467501
[TBL] [Abstract][Full Text] [Related]
47. Substituted isoxazole analogs of farnesoid X receptor (FXR) agonist GW4064.
Bass JY; Caldwell RD; Caravella JA; Chen L; Creech KL; Deaton DN; Madauss KP; Marr HB; McFadyen RB; Miller AB; Parks DJ; Todd D; Williams SP; Wisely GB
Bioorg Med Chem Lett; 2009 Jun; 19(11):2969-73. PubMed ID: 19410460
[TBL] [Abstract][Full Text] [Related]
48. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice.
Kim I; Morimura K; Shah Y; Yang Q; Ward JM; Gonzalez FJ
Carcinogenesis; 2007 May; 28(5):940-6. PubMed ID: 17183066
[TBL] [Abstract][Full Text] [Related]
49. C-reactive protein upregulates receptor for advanced glycation end products expression and alters antioxidant defenses in rat endothelial progenitor cells.
Chen J; Huang L; Song M; Yu S; Gao P; Jing J
J Cardiovasc Pharmacol; 2009 May; 53(5):359-67. PubMed ID: 19276989
[TBL] [Abstract][Full Text] [Related]
50. Farnesoid X receptor agonist GW4064 ameliorates lipopolysaccharide-induced ileocolitis through TLR4/MyD88 pathway related mitochondrial dysfunction in mice.
Liu HM; Liao JF; Lee TY
Biochem Biophys Res Commun; 2017 Aug; 490(3):841-848. PubMed ID: 28647362
[TBL] [Abstract][Full Text] [Related]
51. Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component.
Szalai AJ; van Ginkel FW; Wang Y; McGhee JR; Volanakis JE
J Immunol; 2000 Jul; 165(2):1030-5. PubMed ID: 10878380
[TBL] [Abstract][Full Text] [Related]
52. A cell-based high-throughput screening assay for Farnesoid X receptor agonists.
Zheng ZH; Lv GP; Si SY; Dong YS; Zhao BH; Zhang H; He JG
Biomed Environ Sci; 2007 Dec; 20(6):465-9. PubMed ID: 18348404
[TBL] [Abstract][Full Text] [Related]
53. Unbinding pathways of GW4064 from human farnesoid X receptor as revealed by molecular dynamics simulations.
Li W; Fu J; Cheng F; Zheng M; Zhang J; Liu G; Tang Y
J Chem Inf Model; 2012 Nov; 52(11):3043-52. PubMed ID: 23101941
[TBL] [Abstract][Full Text] [Related]
54. Comparison of effects of VDR versus PXR, FXR and GR ligands on the regulation of CYP3A isozymes in rat and human intestine and liver.
Khan AA; Chow EC; van Loenen-Weemaes AM; Porte RJ; Pang KS; Groothuis GM
Eur J Pharm Sci; 2009 May; 37(2):115-25. PubMed ID: 19429418
[TBL] [Abstract][Full Text] [Related]
55. Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.
Deng G; Li W; Shen J; Jiang H; Chen K; Liu H
Bioorg Med Chem Lett; 2008 Oct; 18(20):5497-502. PubMed ID: 18815030
[TBL] [Abstract][Full Text] [Related]
56. Profile of the bovine acute-phase response following an intravenous bolus-dose lipopolysaccharide challenge.
Carroll JA; Reuter RR; Chase CC; Coleman SW; Riley DG; Spiers DE; Arthington JD; Galyean ML
Innate Immun; 2009 Apr; 15(2):81-9. PubMed ID: 19318418
[TBL] [Abstract][Full Text] [Related]
57. Hop bitter acids efficiently block inflammation independent of GRalpha, PPARalpha, or PPARgamma.
Van Cleemput M; Heyerick A; Libert C; Swerts K; Philippé J; De Keukeleire D; Haegeman G; De Bosscher K
Mol Nutr Food Res; 2009 Sep; 53(9):1143-55. PubMed ID: 19655312
[TBL] [Abstract][Full Text] [Related]
58. Suppressed acute phase response to LPS-induced hepatic injury in Smad3-deficient mice.
Li JH; Lv KY; Li HY; Xia ZF
Mol Immunol; 2009 Jan; 46(3):362-5. PubMed ID: 19058853
[TBL] [Abstract][Full Text] [Related]
59. Gfi1 negatively regulates T(h)17 differentiation by inhibiting RORgammat activity.
Ichiyama K; Hashimoto M; Sekiya T; Nakagawa R; Wakabayashi Y; Sugiyama Y; Komai K; Saba I; Möröy T; Yoshimura A
Int Immunol; 2009 Jul; 21(7):881-9. PubMed ID: 19505891
[TBL] [Abstract][Full Text] [Related]
60. Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR).
Mehlmann JF; Crawley ML; Lundquist JT; Unwalla RJ; Harnish DC; Evans MJ; Kim CY; Wrobel JE; Mahaney PE
Bioorg Med Chem Lett; 2009 Sep; 19(18):5289-92. PubMed ID: 19683924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
